Background: Major depressive disorder (MDD) is inconsistently associated with elevations in proinflammatory cytokines and neuropeptides. We used a skin sweat patch, recently validated in healthy control subjects, and recycling immunoaffinity chromatography to measure neuroimmune biomarkers in patients with MDD mostly in remission.
levated cytokine levels have been reported in subjects with major depressive disorder (MDD) with inconsistent results (1, 2) . Reported alterations in the hypothalamicpituitary-adrenal (HPA) axis and autonomic and pain mediators, including vasoactive intestinal peptide (VIP), neuropeptide Y (NPY), substance P (SP), and calcitonin-gene-related peptide (CGRP) could contribute to this immune dysregulation (3, 4) .
Elevated cytokines in MDD have been linked to osteoporosis, diabetes, cardiovascular disease, sleep disturbances, and decreased pain threshold (5) . We recently reported low bone mass (5) , increased levels of prothrombotic factors (6) , and various pain syndromes (4) in a prospectively assembled cohort of young premenopausal women with MDD.
The aim of the current study was to evaluate neuroimmune biomarkers in sweat in women with MDD, mostly in clinical remission. We measured proinflammatory cytokines (interleukin-1 alpha [IL-1␣], interleukin-1 beta [IL-1␤], interleukin-6 [IL-6], tumor necrosis factor-alpha [TNF␣] , and interleukin-8 ), and NPY, VIP, SP and CGRP in a noninvasive manner using a sweat patch recently validated in normal control subjects (7) . We collected blood to verify that analyte levels in sweat correlated with plasma levels. We used recycling immunoaffinity chromatography (RIC), a highly sensitive and specific methodology, to measure multiple analytes in minute volumes (8, 9) .
We found that cytokines and neuropeptides quantified in sweat patches closely correlate with plasma levels. Women with MDD, mostly in clinical remission, exhibited substantial increases in proinflammatory cytokines and sympathetic and sensory neuropeptides. Biomarker levels were strongly correlated with depressive symptomatology and could account for the increased comorbidities associated with depression.
Methods and Materials

Participants and Study Design
This was an ancillary study to the POWER (Premenopausal, Osteopenia/Osteoporosis, Women, Alendronate, Depression), Study, a prospective study of bone turnover in 21-to 45-year-old premenopausal women with MDD (5, 6) . A convenience sample of 20 consecutive women with MDD and 19 consecutive healthy control women wore two skin patches for 24 hours. Part of the data from nine of the healthy control subjects described here was previously reported (7) . Psychiatric evaluation was conducted using the Structured Clinical Interview for DSM-IV (SCID). Current severity of depression and anxiety was evaluated with the Hamilton Depression Rating Scale (HAM-D) and the Hamilton Anxiety Rating Scale (HAM-A). Inclusion criteria were previously described (6). This study was approved by the Institutional Review Board of the National Institute of Mental Health and registered under Clinicaltrials.gov, Identifier: NCT00006180. Written consent was obtained.
Materials
Sweat patches, manufactured by Pacific Biometrics, Inc. (Irvine, California) and PharmChem Inc. (Fort Worth, Texas) were previously validated for measurement of pyridinoline and deoxypyridinoline in sweat and urine (10) and sweat cytokines (7).
Assays for Cytokine and Neuropeptide Measures
Interleukin-1␣, IL-1␤, IL-6, TNF␣, IL-8, VIP, NPY, SP, and CGRP were measured in the sweat patch and plasma by RIC coupled with laser-induced fluorescence detection, as previously described (8, 11) . Analyses were performed by T.M.P. (National Institute of Biomedical Imaging and Bioengineering [NIBIB] , National Institutes of Health [NIH]) who was blinded to group allocation. Analyte identity was confirmed by mass spectrometry and matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) using recombinant IL-1␣, IL-␤, IL-6, TNF␣, IL-8, VIP, NPY, SP, and CGRP as standards. Previous studies comparing RIC with commercially available enzyme-linked immunosorbent assay (ELISA) assays showed r 2 ϭ .9151 to .9855 (least squares linear regression analysis) (8,9,11) with limit of sensitivity for RIC ϭ 1.6 to 2.8 pg/mL for analytes reported here. Intra-assay and interassay coefficients of variation Ͻ 6.03 Ϯ .33 (Supplement 1).
Assays for Cortisol and Catecholamines
All analyses were performed at the NIH Clinical Center Department of Laboratory Medicine and Mayo Medical Laboratory. Serum 8:00 AM cortisol was measured with the DPC Immulite-2000 chemiluminescent immunoassay (Los Angeles, California). Urinary epinephrine, norepinephrine (NE), and dopamine and 24-hour urinary free cortisol (UFC) were performed by high-performance liquid chromatography (HPLC).
Data Analysis
Differences between groups were tested using independent sample t test or Mann-Whitney U test for continuous variables and Fisher exact test for categorical variables. Spearman correlations were used to describe the bivariate relationships between sweat and plasma levels of cytokines and neuropeptides, as well as between HAM-D and HAM-A scores and biomarker levels. Hierarchical multiple regression analyses was performed. Differences between groups in sweat and plasma analytes were confirmed by testing the percent variance gained by adding a dummy coded group predictor, after controlling for body mass index (BMI) and age (analysis of covariance [ANCOVA]).
Results
Women in the MDD group had similar demographic characteristics and a slightly higher BMI compared with healthy control subjects ( Table 1 ). Seventeen out of 19 patients were mildly depressed at the time of sampling, as indicated by HAM-D scores below 20. One patient had a HAM-D score of 22, and one had a score of 30. As depicted in Table 2 , IL-1␣, IL-1␤, IL-6, TNF␣, IL-8, NPY, SP, and CGRP were significantly higher and VIP was significantly lower by several fold in the MDD group compared with healthy control subjects in both sweat patch eluates and plasma (p Ͻ .0001).
In the MDD group, all biomarkers showed strong and significant correlations between sweat patch and plasma levels (Table  3 ; r ϭ .73 to .99; p Ͻ .001). In the control group, these correlations were more variable and less robust partly because of lower values. Interleukin-1␣, IL-1␤, TNF␣, and IL-8 strongly correlated in plasma and sweat patch eluates but there was little or variable correlation for IL-6, VIP, NPY, SP, and CGRP in control subjects (Table 3) . These correlations remained after controlling for age and BMI (Table 4) . Bivariate analysis showed a strong correlation between biomarker levels and symptom severity for both depression and anxiety, as measured by HAM-D and HAM-A scales, which were remarkably consistent between plasma and sweat, even after controlling for age and BMI (Table 5) . Data reported as mean Ϯ SD and ratio/percent ratio. Table shows demographic and clinical characteristics of study participants. Inclusion criteria required at least one episode of MDD within the last 3 years (DSM-IV). All medications were recorded. The control group was matched by age (3 years) and BMI (two units). All patients and control subjects were in good general health. Data from three subjects were excluded due to 1) a cutaneous reaction in the area where the sweat patches were applied; 2) a subsequent diagnosis of a chronic pain disorder; and 3) the research chart could not be located.
BMI, body mass index; GAF, global assessment of functioning; MDD, major depressive disorder; NA, not applicable.
c Clinical remission is defined here as a Hamilton Depression Scale score below 20, which usually defines mild depression.
There were no differences in 8:00 AM serum cortisol, UFC, and urinary NE, epinephrine, and dopamine (data not shown) between clinical groups.
Discussion
Premenopausal women with MDD, mostly in remission, exhibited several fold elevations of proinflammatory cytokines and sympathetic (NPY) and sensory (SP and CGRP) neuropeptides and diminished parasympathetic-associated neuropeptide, Table shows concentrations of plasma and sweat patch cytokines (pg/ mL) and neuropeptides in patients with MDD and in healthy control subjects. Data are reported as median and range, MDD versus healthy control subject differences in plasma (Mann-Whitney U tests, ps Ͻ .0001) and in sweat (ps Ͻ .0001) for all analytes. As vacuum extraction was used to recover analytes from the patch, standardization of sweat volume was performed by measuring total protein rather than using sodium and potassium as internal references as previously described (20) . For 11 subjects, levels of IL-1␣ were below the assay cutoff limit of .5 pg/mL. As a result, data from these subjects were omitted from the analysis and degrees of freedom were corrected to account for the lower sample size.
CGRP, calcitonin-gene-related peptide; IL-6, interleukin-6; IL-8, interleukin-8; IL-1␣, interleukin-1 alpha; IL-1␤, interleukin-1 beta; MDD, major depressive disorder; NPY, neuropeptide Y; SP, substance P; TNF␣, tumor necrosis factor-alpha; VIP, vasoactive intestinal peptide. CGRP, calcitonin-gene-related peptide; IL-6, interleukin-6; IL-8, interleukin-8; IL-1␣, interleukin-1 alpha; IL-1␤, interleukin-1 beta; MDD, major depressive disorder; NPY, neuropeptide Y; SP, substance P; TNF␣, tumor necrosis factor-alpha; VIP, vasoactive intestinal peptide. Table shows hierarchical regression analysis relating age and BMI to plasma and sweat levels of cytokines and neuropeptides. Both plasma and sweat values were natural log-transformed prior to estimation to normalize the distribution and to correct heteroscedasticity. Analyses were performed using Prism version 3:0 for Windows (GraphPad Software, San Diego, California) and the R statistical computing environment (version 2.3.1; R Development Core Team, R Foundation for Statistical Computing, Vienna, Austria). An ␣ of .05 was used in all significance tests.
BMI, body mass index; CGRP, calcitonin-gene-related peptide; IL-6, interleukin-6; IL-8, interleukin-8; IL-1␣, interleukin-1 alpha; IL-1␤, interleukin-1 beta; NPY, neuropeptide Y; SP, substance P; TNF␣, tumor necrosis factoralpha; VIP, vasoactive intestinal peptide. VIP, in sweat. These levels strongly correlated with depressive and anxiety symptomatology, even after controlling for BMI, suggesting that symptom severity rather than disease classification per se may be related to biomarker expression. The skin patch coupled with RIC, a highly sensitive analytical method for multiple biomarker measurement, previously validated in healthy control subjects (7) allowed identification of a specific pattern of neuroimmune dysregulation not previously detected in mildly depressed women. Analytes in the sweat patch strongly correlated with plasma levels, supporting this approach as a valid method for biomarker measurement. This methodology avoids confounds to biomarker measurements associated with previous methods of sweat collection (exercise [12] , sauna heat [13] , and blood drawing [2] ). Our findings of elevated proinflammatory cytokines are consistent with previous reports in patients with MDD (14) , although conflicting results have been described (2) . An elevation in proinflammatory cytokines of this magnitude substantially increases medical morbidity including osteoporosis, cardiovascular disease, and metabolic disorders (15) . Cytokines also regulate neurotransmitters, hormones, and neuropeptides (16) and modulate many behaviors, including mood and pain, which are altered in patients with depression (1).
The lower VIP levels are consistent with reduced parasympathetic tone that has been reported in depression and with the effectiveness of parasympathetic vagal stimulation in treatment of refractory depression (17) .
The elevated sympathetic and sensory-associated neuropeptides in both sweat patch eluates and plasma in subjects with mild MDD are consistent with their role in depression, although lower cerebrospinal fluid (CSF) NPY has been reported in first-episode depressed patients (18) . Since most patients were pharmacologically treated and antidepressants upregulate central NPY synthesis, increased NPY in these subjects could be related to use of these medications.
This pattern of higher levels of proinflammatory cytokines, lower VIP (parasympathetic activity), and higher NPY (sympathetic activity) in patients with MDD in remission could be associated with increased cardiovascular risk in these patients.
The elevated levels of SP and CGRP are consistent with previous reports of the role of these peptides in pain perception and of painful somatic symptoms correlating with depression severity in up to two thirds of patients with MDD (4).
The normal plasma and urinary cortisol and urinary catecholamine levels observed here have been reported elsewhere (5) in MDD and are consistent with these patients being mostly in a state of remission.
The limitations of the current study include small sample size and treatment with antidepressants, which can in some cases modulate the inflammatory response (19) . Some studies indicate that antidepressants inhibit proinflammatory and stimulate antiinflammatory cytokine production, although others show varying effects (19) . Although we found significant biomarker alterations in this small sample, larger studies in patients on and off medication are needed to confirm and extend these results.
In summary, we found, using a skin sweat patch combined with RIC, that women with mild MDD, treated and in remission, show patterns of elevated proinflammatory cytokines and altered neuropeptides that could predispose not only to osteoporosis, as we recently reported in this cohort (5) , but also to cardiovascular diseases, diabetes, and other medical consequences. Furthermore, levels of biomarkers correlate strongly with symptoms of depression and anxiety. This noninvasive method can be used to measure a variety of biomarkers simultaneously and is a valid alternative when blood collection is unfeasible.
